Of the three companies addressing the unmet medical need that exits for Alopecia Areata, both Concert Pharmaceuticals, and Lilly, have officially released SALT 20 scores. With both companies completing either phase 2 or phase 3 clinical trials, we can make comparison's from the information the companies have released to the public. Lilly has completed two phase 3's Brave-AA1, Brave-AA2 with drug Baricitinib, and Concert has completed a phase 2 with CTP-543. Both have initiated two dosing arms in their trials.
Without considering safety issues for either CTP-543, Baricitinib or Retlecitinb at this time, CTP-543's 12 mg dose appears to have the strongest effect for patients with 42% achieving SALT equal or below a score of 20.
Pfizer has released Ritlecitinib phase 2/3 clinical data Abstract 41, but did not break out the SALT 20 scores, but has issued long-term 48 week results. Below is a comparison of Ritlecitinib 48 week and CTP-543 52 week (Mean SALT Score) results that the companies have released to the public.
Note that a SALT score of zero is a full head of hair. So the lower the SALT score from baseline, the more hair growth that has occurred. The baseline score (SALT 88.1) was derived from Pfizer's phase 2 part of the phase 2/3 clinical trial. Concert has used the 12 mg dose from two clinical trials to derive a baseline average score of SALT 86.5. Thank you for reading.
